Activity of a 0.05% triamcinolone acetonide/laurocapram formulation: double-blind, randomized comparison with standard 0.1% triamcinolone acetonide creams and with mild (Class VI) to potent (Class III) topical corticosteroids

Azone® enhances clinical effectiveness of an optimized formulation of triamcinolone acetonide in atopic dermatitis

“…The vasoconstriction assay has shown that the combination of 0.05% triamcinolone acetonide and laurocapram is a more effective vasoconstrictor than a 0.1% triamcinolone acetonide formulation without laurocapram 18 . Because vasoconstriction correlates with the clinical activity of corticosteroids, 19,20 it is thought that 0.05% triamcinolone acetonide with laurocapram (TNX) might provide therapeutic advantages over standard triamcinolone formulations.…”